FDA still mum on biosimilar interchangeability guidance

FDA declined to say when it expects to release guidance on the interchangeability of biosimilars, and the guidance was not included on a list of new and revised draft guidances that the agency plans to publish this year. The list does include guidances on the submission of clinical pharmacology data as evidence of biosimilarity and formal meetings between the FDA and biosimilar sponsors or applicants. ...